Periodic Reporting for period 1 - kINPen (Developing a high-innovative portable cold plasma device for efficient healing of chronic wounds in veterinary medicine)
Okres sprawozdawczy: 2019-01-01 do 2019-04-30
The veterinary sector urgently needs to revolutionize their treatment methods in order to solve the present antibiotic overconsumption and related growing resistance. Currently, the antibiotic resistance is one of the world’s most pressing public health problems. It is estimated that about 33,000 people die every year in the EU/EEA as a direct consequence of an infection due to bacteria resistance to antibiotics. Moreover, it is found that around 70% of all antibiotics administered are used for animals. This constitutes an important market opportunity for new technologies. Current non-pharmacological infection treatments such as ultrasound, electrical stimulation, laser or light-emitting diode (LED), are less efficient, given their cost, unpleasant feeling, treatment-time and required area.
Therefore, neoplas GmbH has successfully developed kINPen®VET, a non-pharmacological, high-innovative and portable cold plasma device for efficient healing of chronic wounds in farm and pet animals (e.g. milk cows, horses, cats, dogs). It stimulates and accelerates physiological wound healing and it is highly effective against typical wound bacteria, multidrug-resistant microorganisms and fungi, obtaining antiviral, antimicrobial, antifungal and anti-inflammatory effects on the treated surface without the need of antibiotics or developing microorganism resistance. It is based on cold plasma and uses the advantages of the Plasma Effect (ionized gas, electrons and ions, as well as radicals, excited species, UV radiation and electromagnetic fields). KINPen®VET will provide a 100% safe and manoeuvrable device, leading to a more cost-effective and sustainable veterinary medical treatment. In addition, in the course of increasing the fight against antibiotic resistance, the chances for kINPen®VET as alternative wound treatment are good for a successful market introduction.
With the support of the European commission kINPen®VET is able to accelerate the upscaling and to keep R&D and pilot line activities on high level to further upgrade the system quality and to develop more technological research about cold plasma. Moreover, kINPen®VET is a great chance to extend the Europe- and worldwide contacts to potential customers. It is important to highlight that kINPen®VET’s commercialization will generate high revenues in the targeted market segments of animal health and wellbeing and organic animal farming (market share 50%). This equals to an approximate number of more than 110.000 systems presenting a turnover of €950 million only in Europe. This ambitious target is reachable by forming a European network of regional suppliers, representatives and costumers in each targeted country.
Therefore, neoplas GmbH has successfully developed kINPen®VET, a non-pharmacological, high-innovative and portable cold plasma device for efficient healing of chronic wounds in farm and pet animals (e.g. milk cows, horses, cats, dogs). It stimulates and accelerates physiological wound healing and it is highly effective against typical wound bacteria, multidrug-resistant microorganisms and fungi, obtaining antiviral, antimicrobial, antifungal and anti-inflammatory effects on the treated surface without the need of antibiotics or developing microorganism resistance. It is based on cold plasma and uses the advantages of the Plasma Effect (ionized gas, electrons and ions, as well as radicals, excited species, UV radiation and electromagnetic fields). KINPen®VET will provide a 100% safe and manoeuvrable device, leading to a more cost-effective and sustainable veterinary medical treatment. In addition, in the course of increasing the fight against antibiotic resistance, the chances for kINPen®VET as alternative wound treatment are good for a successful market introduction.
With the support of the European commission kINPen®VET is able to accelerate the upscaling and to keep R&D and pilot line activities on high level to further upgrade the system quality and to develop more technological research about cold plasma. Moreover, kINPen®VET is a great chance to extend the Europe- and worldwide contacts to potential customers. It is important to highlight that kINPen®VET’s commercialization will generate high revenues in the targeted market segments of animal health and wellbeing and organic animal farming (market share 50%). This equals to an approximate number of more than 110.000 systems presenting a turnover of €950 million only in Europe. This ambitious target is reachable by forming a European network of regional suppliers, representatives and costumers in each targeted country.
1.1 Identification of the most promising regions with regard to the veterinary medicine and industrial animal production sector (especially in the lucrative markets of equine medicine, livestock medicine and organic production)
1.1 Market analysis in European regions. (wound treatment type, price & benefits comparison)
1.2 Profile of suitable clients (economic losses due to treatment of animal wounds, industry size)
1.3 Assessment of the price trends of side streams of the veterinary medicine and industrial sector of organic animal production for nutrition medium and price elasticity of the demand
2 Identification of potential local distributors or commercial agents and setup of a commercialization network
3 Determination of KINPen®VET systems and commercialization strategies adapted to each region and industry
4 Compilation of a database of potential customers, end-users and competitors
5 Determination of standards, technical certifications, and norms needed to be complied
6 Business Plan
1.1 Market analysis in European regions. (wound treatment type, price & benefits comparison)
1.2 Profile of suitable clients (economic losses due to treatment of animal wounds, industry size)
1.3 Assessment of the price trends of side streams of the veterinary medicine and industrial sector of organic animal production for nutrition medium and price elasticity of the demand
2 Identification of potential local distributors or commercial agents and setup of a commercialization network
3 Determination of KINPen®VET systems and commercialization strategies adapted to each region and industry
4 Compilation of a database of potential customers, end-users and competitors
5 Determination of standards, technical certifications, and norms needed to be complied
6 Business Plan
kINPen®VET positions itself as the first physical antibiotic alternative with the same ease of use and declare war on antibiotic resistance. Our compact and mobile system methodology will pave the way for veterinary medicine to develop new wound treatment alternatives without develop any microorganism resistance. The traditional method for treating wound infections is the administration of antibiotics and it is a common practice in the veterinary medicine sector. However, antibiotic resistance occurs when bacteria change in response to the use of these medicines and misuse of antibiotics in humans and animals is accelerating the process. When infections can no longer be treated by first-line antibiotics, more expensive medicines must be used. A longer duration of illness and treatment, increases costs as the livestock and pets owners and societies. As the market for veterinary health application is growing rapidly several non-pharmacological treatments of infections such as laser needle or light-emitting diode (LED), the Hyperbaric Oxygen Therapy and the Negative Pressure Wound Therapy are available on the market. However, their costs are high and inefficient, which gives neoplas GmbH the opportunity to dictate the market.
kINPen®VET's excellent stability and acceleration physiological wound healing; it is 100% effective against typical wound bacteria, multidrug-resistant microorganisms, and fungi will enable the European veterinary medicine and livestock sector to reduce cost for treatment, sacrifice and time. Due to its synergetic combination of its components, plasma has antiviral, antimicrobial, antifungal, anti-inflammatory and wound healing effects on the treated surface. At the same time, plasma activates the immune system and supports the wound healing through cellular stimulation, whilst only causing minimum creation of scar tissue. The ability of the plasma to penetrate cracks allows good access to deep and hidden wounded areas such as caverns, cavities and hair follicles.
In addition, the treatment of show horses in particular offers a good entry opportunity for the kINPen®VET, as antibiotics are on the doping list of the Federal Association for Equestrian Sports and Breeding. The kINPen®VET offers the possibility to eliminate harmful bacteria without endangering the horse's ability to compete, as well as, there is currently great interest in the Arab world (with the aim of using the device for the treatment of racing camels), further inquiries have been received from Finland and France. According to a report by Transparency Market Research, the global equine healthcare market is anticipated to rise at a healthy CAGR of 4.2% during the forecast period of 2017 and 2025. In addition, in the last several years, the global market of Equine Pharmaceuticals and Supplements developed rapidly, with an average growth rate of 4.52% from 2013 to 2017. Currently great interest in the Arab world (with the aim of using the device for the treatment of racing camels), further inquiries have been received from Finland and France. kINPen®VET contributes to solving a public health problem with global implications.
kINPen®VET's excellent stability and acceleration physiological wound healing; it is 100% effective against typical wound bacteria, multidrug-resistant microorganisms, and fungi will enable the European veterinary medicine and livestock sector to reduce cost for treatment, sacrifice and time. Due to its synergetic combination of its components, plasma has antiviral, antimicrobial, antifungal, anti-inflammatory and wound healing effects on the treated surface. At the same time, plasma activates the immune system and supports the wound healing through cellular stimulation, whilst only causing minimum creation of scar tissue. The ability of the plasma to penetrate cracks allows good access to deep and hidden wounded areas such as caverns, cavities and hair follicles.
In addition, the treatment of show horses in particular offers a good entry opportunity for the kINPen®VET, as antibiotics are on the doping list of the Federal Association for Equestrian Sports and Breeding. The kINPen®VET offers the possibility to eliminate harmful bacteria without endangering the horse's ability to compete, as well as, there is currently great interest in the Arab world (with the aim of using the device for the treatment of racing camels), further inquiries have been received from Finland and France. According to a report by Transparency Market Research, the global equine healthcare market is anticipated to rise at a healthy CAGR of 4.2% during the forecast period of 2017 and 2025. In addition, in the last several years, the global market of Equine Pharmaceuticals and Supplements developed rapidly, with an average growth rate of 4.52% from 2013 to 2017. Currently great interest in the Arab world (with the aim of using the device for the treatment of racing camels), further inquiries have been received from Finland and France. kINPen®VET contributes to solving a public health problem with global implications.